Figure 7From: E2F4 regulatory program predicts patient survival prognosis in breast cancerApplication of the E2F4 signature for predicting patient survival times in six cancer types. In each cancer dataset, patients are stratified into a group with positive E2F4 activity and a group with negative E2F4 activity. The difference in their survival curves is calculated using the log-rank test.Back to article page